Liquidia Corporation reported total revenue of $171.7 million and net income of $74.7 million for the second quarter of 2026, marking its fourth consecutive quarter of increasing profitability. The results were driven by the rapid commercial scaling of YUTREPIA, which has captured a significant share of the growing inhaled prostacyclin market since its 2025 launch.
Key Highlights
- YUTREPIA net product sales reached $170.4 million, representing a 31% sequential increase over the first quarter of 2026.
- Patient adoption remains robust with approximately 5,900 unique prescriptions and over 5,000 patients treated since launch, supported by a prescriber base of more than 1,100 physicians.
- The company strengthened its balance sheet, ending the quarter with $284.2 million in cash and cash equivalents, a $61.4 million increase from the prior quarter.